Clinical trials
Bone Marrow Transplant clinical trials
Below are recruiting bone marrow transplant clinical trials, each written for real people, not researchers. We’re tracking 188 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07046078RecruitingPhase 2
Chemo, radiation, and donor transplant for older adults with high-risk AML
This trial tests a combination of chemotherapy (FLAG-Ida) followed by low-dose total body radiation and a stem cell transplant from a donor. It is for people age 60 and older with newly diagnosed high-risk blood cancers, aiming to improve outcomes with a less intense transplant preparative regimen.
Seattle, WashingtonAges 18 years+ - NCT07145411Recruiting
Bone marrow transplant trial for patients 12 to 80
This trial provides bone marrow for transplant to patients who are already considered good candidates for a donor transplant by their own doctor. The goal is to see if using this bone marrow product is safe and helpful.
Birmingham, AlabamaAges 12–80 - NCT07365306RecruitingPhase 2
Epcoritamab with chemo before stem cell transplant for DLBCL
This trial tests a combination of drugs — epcoritamab, rituximab, gemcitabine, and oxaliplatin — as a ‘salvage’ therapy for people with diffuse large B-cell lymphoma that has come back or not responded to initial treatment. The goal is to shrink the lymphoma enough so you can go on to a stem cell transplant using your own cells.
Duarte, CaliforniaAges 18 years+ - NCT01163578Recruiting
Using test results to improve outcomes after organ or marrow transplant
This study looks at “biomarkers,” which are measurable lab signals, in people who have had an organ or bone marrow transplant. The goal is to use these test results to better predict and improve transplant outcomes.
Pittsburgh, PennsylvaniaAges Any age - NCT02828592RecruitingPhase 2
Transplant trial for severe aplastic anemia with related donor
This Phase 2 study tests a bone marrow transplant from a closely matched related donor, plus medicine after the transplant to help prevent immune complications. It may be an option if you have severe aplastic anemia and meet specific health and lab requirements.
Atlanta, GeorgiaAges 1–75 - NCT07527104Recruiting
Bone marrow cells and rehabilitation for cerebral palsy in young children
This trial tests whether transplanting cells from a child's own bone marrow, combined with rehabilitation therapy, can improve movement and function in young children with cerebral palsy caused by birth-related brain injury or bleeding. The goal is to see if this approach helps children move better and become more independent.
Hanoi, HanoiAges 6 months–18 years - NCT03816319RecruitingPhase 1
TAK-243 for leukemia or MDS that has returned or not improved
This trial tests a new drug called TAK-243 in people with acute myeloid leukemia (AML) or myelodysplastic syndrome with increased blasts (MDS-IB) that has come back or hasn't gotten better after treatment. The goal is to see if TAK-243 can help when other options have stopped working.
Tampa, FloridaAges 18 years+ - NCT03739814RecruitingPhase 2
Test inotuzumab, blinatumomab, and possibly ponatinib for CD22 ALL
This Phase 2 study tests a combination of medicines (inotuzumab ozogamicin and blinatumomab), with or without ponatinib, for people with CD22-positive B-cell acute lymphoblastic leukemia (ALL). It aims to improve remission and control leukemia cells, including in the bone marrow.
Birmingham, AlabamaAges 18 years+ - NCT07645469RecruitingPhase 1
WT1 T Cell Therapy With Azacitidine for AML Minimal Residual Disease
This trial tests a new type of immune therapy using your own T cells (white blood cells) that are trained to fight AML cancer cells. It's designed for patients whose AML has mostly gone away with chemotherapy but still has traces of cancer detectable in blood or bone marrow tests.
Seattle, WashingtonAges 18 years+ - NCT06649812RecruitingPhase 2
Testing a combination targeted therapy (ViPOR) for aggressive B-cell lymphoma
This trial tests a new combination of targeted drugs called ViPOR for people with aggressive B-cell lymphoma that has come back or not responded to previous treatment. The goal is to see if this treatment can help when standard therapies haven't worked.
Tucson, ArizonaAges 18 years+ - NCT07133997RecruitingPhase 1
Combination therapy for relapsed CD19+ B-cell leukemia
This trial tests a new combination of three drugs for patients with relapsed or treatment-resistant CD19-positive B-cell acute lymphoblastic leukemia. It aims to see if adding the drugs venetoclax and asparaginase to blinatumomab can improve outcomes.
Duarte, CaliforniaAges 12–55 - NCT04195633RecruitingPhase 2
Haploidentical donor stem cell transplant to treat blood cancers
This Phase 2 trial tests whether a specific stem cell transplant method (from a related “half-matched” donor) plus conditioning chemo and radiation can improve outcomes for several blood cancers. It may help people whose cancer is in remission but still considered high risk, or those who have had limited response after prior treatment.
Seattle, WashingtonAges 6 months+ - NCT04370301RecruitingPhase 2
Reduced-intensity stem cell transplant with JAK inhibitor for myelofibrosis
This study tests giving a JAK inhibitor before and after a reduced-intensity stem cell transplant to treat primary or secondary myelofibrosis. The goal is to improve disease control while using a less harsh transplant approach.
Seattle, WashingtonAges 18–70 - NCT04375631RecruitingPhase 1
Study of chemo plus donor stem cell transplant for blood cancers
This Phase 1 trial tests a specific chemotherapy plan followed by a reduced-intensity donor stem cell transplant for people with relapsed or treatment-resistant acute myeloid leukemia (AML), certain myelodysplastic syndromes (MDS), or chronic myelomonocytic leukemia (CMML). It may help by using donor stem cells to rebuild the bone marrow after intensive cancer treatment, in people who are not responding well to standard therapies.
Seattle, WashingtonAges 18 years+ - NCT04546399RecruitingPhase 2
Blinatumomab with or without nivolumab for first relapse ALL
This study compares blinatumomab alone versus blinatumomab plus nivolumab in young people whose B-cell ALL has returned for the first time. It aims to see whether adding nivolumab improves control of the leukemia after relapse.
Birmingham, AlabamaAges 1–30 - NCT04659616RecruitingPhase 1
Pemigatinib after standard chemo for newly diagnosed AML
This Phase 1 trial studies whether adding pemigatinib after standard “7+3” chemotherapy can improve outcomes in certain newly diagnosed acute myeloid leukemia (AML) patients. It aims to find a safe dose and see how well the drug works in a very specific AML genetic group.
Portland, OregonAges 18 years+ - NCT04870944RecruitingPhase 1/Phase 2
CBL0137 for children with advanced solid or brain tumors
This early-phase study tests CBL0137 in children and teens whose cancer has come back or is not responding to treatment. It is also for some specific hard-to-treat brain tumors, to see if the drug is safe and can work against the cancer.
Birmingham, AlabamaAges 1–21 - NCT04892277RecruitingPhase 1
CD19 CAR-T for adults with hard-to-treat B-cell cancers
This Phase 1 trial tests a lab-made immune therapy (CD19 CAR-T) for adults whose B-cell cancers have come back or did not respond to treatment. It may help your immune system better recognize and attack cancer cells, but it is early research, so benefits and risks are still being defined.
Rochester, MinnesotaAges 18 years+ - NCT05755087RecruitingPhase 1
Tegavivint for relapsed or hard-to-treat lymphoma patients
This Phase 1 trial tests tegavivint, a new investigational medicine, for certain types of aggressive B-cell lymphoma that have come back or did not respond to prior treatment. It may help shrink the lymphoma and learn how safe and effective the drug is in this setting.
Columbus, OhioAges 18 years+ - NCT05847569RecruitingPhase 2
Testing alternating doses of belantamab for hard-to-treat myeloma
This Phase 2 trial tests whether alternating doses and schedules of belantamab mafodotin can help people with multiple myeloma that has returned or kept progressing after several prior treatments. You may be eligible if your disease has specific measurable signs and your blood counts and organs are healthy enough for study treatment.
Jacksonville, FloridaAges 18 years+ - NCT05910801RecruitingPhase 2
Tafasitamab plus lenalidomide and venetoclax for relapsed lymphoma
This Phase 2 trial studies tafasitamab together with lenalidomide and venetoclax in people with mantle cell lymphoma (MCL) that has come back or did not respond to prior treatment. It may help shrink the lymphoma and improve disease control when standard options have not worked.
Rochester, MinnesotaAges 18 years+ - NCT06042725RecruitingPhase 1
Testing new drug combos for multiple myeloma with a specific gene change
This trial tests if adding venetoclax to standard myeloma treatments can help patients with a specific gene change called t(11;14). There are different treatment combinations for people newly diagnosed or who have already tried other therapies.
Rochester, MinnesotaAges 18 years+ - NCT06172296RecruitingPhase 3
Dinutuximab plus transplant for high-risk neuroblastoma
This trial tests adding a targeted drug called dinutuximab to standard chemotherapy, surgery, and a stem cell transplant for children and young adults with a new diagnosis of high-risk neuroblastoma. The goal is to see if this combination helps more patients stay in remission.
Birmingham, AlabamaAges Up to 30 years - NCT06195891RecruitingPhase 1
Orca-T stem cell transplant for older adults with blood cancer
This study tests a new way to give donor stem cells (called Orca-T) after a special type of chemotherapy and radiation. It is for people aged 60–75 with certain blood cancers that have not responded well to standard treatments.
Duarte, CaliforniaAges 60 years+
Hear when a new Bone Marrow Transplant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for bone marrow transplant?
- Yes. Clin2 currently lists 188 recruiting bone marrow transplant studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a bone marrow transplant trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a bone marrow transplant trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.